Skip to main content
    A

    Alpha Tau Medical Ltd (DRTS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $13.72
    +0.42 (+3.16%)

    Market Cap: $1.30B

    Last updated: Nov 06, 2026 at 4:42 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    55%(11/20)
    Avg Surprise
    -37.13%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.15
    Range$-0.16 - $-0.13
    4 analysts
    EPS RevisionsNo revisions (7d)
    1
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.14-6.1%
    60d ago$-0.14-3.5%
    30d ago$-0.150.0%
    7d ago$-0.150.0%
    Current$-0.15
    Revenue Consensus
    $324330
    Range$0 - $500000
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.54
    Range$-0.67 - $-0.14
    5 analysts
    Revenue Consensus
    $332830
    Range$-611500 - $898500
    3 analysts
    Last 12 of 23 reported quarters and 2 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-0.54$-0.67 - $-0.14--5--
    Sep 26EST
    		-$-0.15$-0.16 - $-0.13--4
    1
    3
    30d
    		-
    Jun 26
    Reported Aug 10
    		$-0.50$-0.14$-0.15 - $-0.13-257.14%Miss4
    1
    3
    30d
    		-284.6%
    Mar 26
    Reported May 18
    		$-0.26$-0.12$-0.13 - $-0.11-116.67%Miss4
    0
    1
    30d
    		-116.7%
    Dec 25
    Reported Mar 9
    		$-0.14$-0.12$-0.13 - $-0.12-13.54%Miss4
    1
    1
    30d
    		-7.7%
    Sep 25
    Reported Nov 20
    		$-0.14$-0.12$-0.12 - $-0.11-16.67%Miss4
    1
    2
    30d
    		-40.0%
    Jun 25
    Reported Aug 11
    		$-0.13$-0.11$-0.13 - $-0.10-18.18%Miss4
    2
    0
    30d
    		-18.2%
    Mar 25
    Reported May 19
    		$-0.12$-0.14$-0.14 - $-0.12+14.29%Beat4
    0
    1
    30d
    		-9.1%
    Dec 24
    Reported Mar 12
    		$-0.13$-0.13$-0.13 - $-0.12+0.00%Beat3
    1
    0
    30d
    		-18.2%
    Sep 24
    Reported Nov 21
    		$-0.10$-0.12$-0.14 - $-0.11+16.67%Beat4
    2
    0
    30d
    		+60.0%
    Jun 24
    Reported Aug 14
    		$-0.11$-0.12$-0.12 - $-0.11+8.33%Beat3
    1
    0
    30d
    		+8.3%
    Mar 24
    Reported May 20
    		$-0.11$-0.13$-0.14 - $-0.11+15.38%Beat4
    No revisions (30d)
    		+8.3%
    Dec 23
    Reported Mar 7
    		$-0.11$-0.12$-0.14 - $-0.10+8.33%Beat4
    No revisions (30d)
    		-120.0%
    Sep 23
    Reported Nov 16
    		$-0.25$-0.12$-0.14 - $-0.11-108.33%Miss3
    No revisions (30d)
    		-525.0%

    Key Metrics

    Valuation
    P/E Ratio-13.19EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-141.70%ROIC-176.93%
    Financial Health
    Debt/Equity0.18xInterest CoverageN/A
    Current Ratio11.09xQuick Ratio11.09x
    Trading Statistics
    Beta1.29Avg Volume505.27K
    52-Week High$15.7952-Week Low$3.43

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$13.35
    SMA 20$13.28
    SMA 50$14.13
    SMA 200$10.76
    EMA 10$13.43
    EMA 20$13.51
    EMA 50$13.67
    EMA 200$11.10

    MACD

    Line: -0.16Signal: -0.26Hist: 0.10

    ADX

    ADX: 22.4+DI: 18.7-DI: 24.3

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down40.0
    PSAR$12.59

    Bollinger Bands

    Upper Band$14.22
    Lower Band$12.35
    %B Position1411%(Upper)
    Band Width0.73

    RSI (14-Day)

    Neutral
    51.2

    Momentum Oscillators

    Stoch %K71.2
    Stoch %D73.3
    Williams %R-28.2
    ROC (10d)4.3%
    Momentum0.56
    CCI (20d)63.8
    MFI (14d)66.6

    Volatility Measures

    ATR (14d)$0.68(5.0%)
    StdDev (20d)0.47
    Hist Vol55.8%(High)

    Volume Flow

    VWAP$13.62
    OBV14.7M
    AD Line6.4M
    CMF (20d)-0.056

    Volume Metrics

    Avg Vol (20d)507.6K
    Vol Ratio0.8x
    VWMA (20d)$13.24

    Pivot Points

    R3$14.92
    R2$14.47
    R1$13.88
    Pivot Point$13.43
    S1$12.85
    S2$12.40
    S3$11.81

    Advanced Oscillators

    TSI-6.73
    Ultimate Osc54.3
    KST-75.00

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of RevenueN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A$1.07MN/A
    Gross ProfitN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A$-1,074,000N/A
    Operating Expenses$13.78M$13.31M$12.60M$10.73M$9.65M$9.31M$10.27M$8.29M$9.05M$8.42M$8.87M$8.93M
    R&D$9.91M$10.97M$9.58M$8.31M$7.01M$7.17M$7.53M$6.17M$6.87M$6.45M$7.49M$6.67M
    SG&A$3.56M$2.10M$2.57M$1.93M$2.18M$1.68M$2.05M$1.59M$1.59M$1.44M$2.00M$1.70M
    Operating Income$-13,782,000$-13,313,000$-12,602,000$-10,730,000$-9,648,000$-9,308,000$-10,274,000$-8,290,000$-9,054,000$-8,424,000$-9,943,000$-8,925,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$31.80M$9.64M$0$2.34M$401,000$0$0$0$0$0$0$2.03M
    Income Before Tax$-45,584,000$-22,950,000$-12,171,000$-11,694,000$-10,049,000$-8,592,000$-9,474,000$-6,924,000$-7,366,000$-7,980,000$-7,357,000$-4,951,000
    Income Tax Expense$229,000$-11,000$-35,000$-8,000$65,000$99,000$2,000$0$3,000$1,000$8,000$-39,000
    Net Income$-45,813,000$-22,939,000$-12,136,000$-11,686,000$-10,114,000$-8,691,000$-9,476,000$-6,924,000$-7,369,000$-7,981,000$-7,365,000$-4,912,000
    EBITDA$-13,782,000$-13,313,000$-11,241,000$-10,730,000$-9,177,000$-9,308,000$-5,397,500$-8,021,500$-8,774,000$-8,155,500$-8,869,000$-8,925,000
    EBIT$-55,052,000$-13,313,000$-12,473,000$-11,476,500$-9,443,500$-9,583,500$-5,673,000$-8,290,000$-9,054,000$-8,424,000$-9,943,000$-8,925,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DRTS

    DRTS Valuation and Fair Value

    P/E
    -13.2x
    P/B
    28.3x
    See GNG's fair value

    DRTS Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    -176.9%
    ROE
    -141.7%

    DRTS Competitors

    CompanyTicker
    Opko Health IncOPK
    Mind Medicine IncMNMD
    Taysha Gene Therapies IncTSHA
    Artivion IncAORT
    STAAR Surgical CompanySTAA
    Tandem Diabetes Care IncTNDM
    Mineralys Therapeutics, Inc. Common StockMLYS
    InnovAge Holding CorpINNV

    Sector: Healthcare

    DRTS Analyst Ratings

    Consensus
    Buy
    Analysts
    5
    Strong Buy
    1
    Buy
    3
    Hold
    1
    Sell
    0
    Strong Sell
    0

    DRTS Bull Case vs Bear Case

    Bull case

    • 80.0% of DRTS's analyst ratings are Buy or Strong Buy.

    Bear case

    • DRTS beat EPS estimates in 25.0% of its last 8 reported quarters.

    DRTS Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -48.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.15
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 3 down

    DRTS Earnings Date

    DRTS reports Nov 24, 2026. The date is estimated.

    DRTS ETF Holders

    GNG tracks 1 ETF that holds DRTS.

    1. ARK Israel Innovative Technology ETF (IZRL), 1.93% of the fund
    Open the ETF Stock Exposure tool for DRTS

    Frequently Asked Questions About DRTS

    When does DRTS report earnings?

    Alpha Tau Medical Ltd (DRTS) is expected to report earnings on Nov 24, 2026.

    Does DRTS pay dividends?

    Alpha Tau Medical Ltd (DRTS) does not currently pay a regular dividend.

    What is DRTS's market cap?

    Alpha Tau Medical Ltd (DRTS) has a market capitalization of $1.30B with a current stock price of $13.72.

    Related stocks

    Sector: Healthcare

    All stocks starting with D

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In